J&J to buy remaining stake in Verb Surgical to strengthen digital surgery portfolio

(Reuters) – Johnson & Johnson said on Friday it would acquire the remaining stake in Verb Surgical Inc, from Verily, Alphabet (NASDAQ:) Inc’s life sciences division.

Bolstering its Ethicon unit, which makes surgical equipment, J&J in 2015 formed an independent company called Verb Surgical with Verily to create smaller, smarter and less costly robotic-assisted systems for surgery. (https://reut.rs/2EBtI9j)

The deal for Verb Surgical is expected to close in the first half of 2020, J&J said without disclosing deal terms.

J&J pushed further into the surgical robotics space with its $3.4-billion acquisition of Auris Health Inc earlier this year. The deal gave J&J access to the privately held company’s surgical robotic scope used in respiratory procedures and the detection of lung cancer.

The acquisition of Auris accelerated J&J’s entry into digital surgery, kicking off a strong pipeline of launches that will take place over the next several years, J&J said on Friday.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.